Cilofexor [17], another FXR agonist, showed a significant reduction in hepatic steatosis, liver biochemistry, and serum bile acids in patients with NASH after 24 weeks of treatment. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.